NICE recommends Novartis Cosentyx® (secukinumab) as the first biologic treatment for hidradenitis suppurativa (HS) since 2016

NICE recommends Novartis Cosentyx® (secukinumab) as the first biologic treatment for hidradenitis suppurativa (HS) since 2016 •    Hidradenitis suppurativa (HS) is a painful, chronic and progressive inflammatory skin disease with over 50% of people reporting a mental health impact1,2 &bu...

Related Keywords

London ,City Of ,United Kingdom ,Ireland ,British ,Dermatol Venereol ,Novartis Cosentyx ,Phil Brady ,Hidradenitis Suppurativa ,Acta Derm Venereol ,John Ingram ,Novartis Pharmaceuticals Corp ,Treatment Fund ,Innovative Medicines Fund ,Twitter ,British Skin Foundation ,Novartis ,Treatment Fund In Wales ,Novartis Pharmaceuticals United Kingdom Ltd ,National Institute For Health ,National Institute ,Care Excellence ,New Treatment Fund ,Clinical Reader ,Consultant Dermatologist ,Chief Operating Officer ,British Skin ,Hidradenitis Suppurativa Clinical Response ,Country President ,Novartis Innovative Medicines United Kingdom ,Novartis United Kingdom ,Final Draft Guidance ,Novartis Pharmaceuticals United Kingdom ,Rev Dis ,Its Effect ,Two Secukinumab Dose Regimens ,Subjects With Moderate ,Severe Hidradenitis Suppurativa ,Provides Sustained Improvements ,Psoriatic Arthritis ,Pooled Safety ,Pharmaceuticals Corp ,Secukinumab Over Five Years ,Moderate To Severe Plaque Psoriasis ,Ankylosing Spondylitis ,Integrated Pooled Clinical Trial ,Post Marketing Surveillance ,Acta Derm ,